Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Genetic polymorphisms contribute to the individual variations of Imatinib mesylate plasma levels and adverse reactions in Chinese GIST patients
- At: 2017 FIP Congress in Stockholm (Sweden)
- Type: Poster
- By: CAI, Weimin (Fudan University, School of Pharmacy, Clinical Pharmacy, Shanghai, China)
- Co-author(s): Jing Liu: Clinical Pharmacy, Fudan University, School of Pharmacy, Shanghai, China
Yuhong Zhou: Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
Hangmei Chen: Clinical Pharmacy, Fudan University, School of Pharmacy, Shanghai, China
Weimin Cai: Clinical Pharmacy, Fudan University, School of Pharmacy, Shanghai, China
BackgroundsImatinib mesylate (IM) has been used in the treatment of Gastrointestinal Stromal Tumors (GIST) patients. However, the clinical efficacy and adverse reactions of IM may considerably vary due to the genetic polymorphisms of its drug-metabolizing enzymes, transporter and nuclear receptor.
AimsThis study aimed to investigate the influence .. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019